Sign in
Taking peopleNo phase

T6A Biomarker for Detection of Bacterial Infection in Newborn Infants

Key facts

Who runs it
Salzburger Landeskliniken
Where
Austria and Poland2 sites in 2 countriesChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
210 people, planned
Started
3 Sept 2026
Expected to end
31 Jan 2029
Type of study
Observational, 2 groups
Record updated
9 September 2026

Who can take part

Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 4 criteriaShow less

Who can take part

  • Newborn infants who require blood testing for screening for bacterial infection OR treating physician suspects bacterial infection in newborn infant
  • Signed informed consent form

Who cannot take part

  • Refusal to participate in study or not providing written informed consent by caregivers/parents
  • Antibiotic treatment of any kind

This trial has no sites in United States.

It has sites in 2 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

This bi-center study aims to assess the efficacy of a new biomarker, N6-threonylcarbamoyladenosine (t6A), for the early diagnosis of Early-Onset Sepsis (EOS) in newborns.

The 2 groups in the trial

  • Patients
  • Controls

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
9 September 2026